ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2695

B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents
Abstract Number: 1754

B3GNT2 Regulates Integrin β3 Glycosylation and Th17/Treg Imbalance in Axial Spondyloarthritis Pathogenesis
Abstract Number: 2346

Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
Abstract Number: 1863

Bag3 in systemic sclerosis: possible therapeutic target and biomarker for pulmonary fibrosis
Abstract Number: 2017

Baseline and 2-year Follow-up of Pulmonary Function Among CTD-ILD Subtypes
Abstract Number: 1107

Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Abstract Number: 1108

Baseline Features, Immunosuppression, and Immune-Related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Abstract Number: 0583

Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
Abstract Number: 0780

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials
Abstract Number: 1975

Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
Abstract Number: 1045

Bayesian Analysis of Factors Associated with Romosozumab Adherence Among Early Adopters in Medicare Beneficiaries
Abstract Number: 0240

Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
Abstract Number: 2028

Behçet’s Syndrome Beyond Endemic Borders: A 24-Year Longitudinal Analysis of Mortality in a Diverse South American Cohort
Abstract Number: 2535

Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region
Abstract Number: 1533

Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Abstract Number: 2453

Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Abstract Number: 0649

Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Abstract Number: 2439

Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
Abstract Number: 0642

Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Abstract Number: 2513

Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
Abstract Number: 1209

Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
Abstract Number: 1241

Beyond Pain Severity in Psoriatic Arthritis: Pain Catastrophizing Independently Impacts Disease Burden and Quality of Life
Abstract Number: 1400

Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease
Abstract Number: 0442

Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Abstract Number: PP07

Beyond the Medication: Creating a Toolbox of Complementary Therapies
Abstract Number: 0136

Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
Abstract Number: 0324

Bile Acids Metabolism in Symptomatic Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study and Genetics of OA Consortium
Abstract Number: 0574

Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
Abstract Number: 1449

Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Abstract Number: 2358

Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
Abstract Number: 2374

Bimekizumab Efficacy And Safety Through 5 Years In Patients With Moderate To Severe Plaque Psoriasis In The US And Canada
Abstract Number: 1439

Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
Abstract Number: 2341

Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Abstract Number: 2347

Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Abstract Number: 1451

Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Abstract Number: 0024

Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease
Abstract Number: 1297

Biologic Therapy for Refractory Juvenile Scleroderma: a retrospective case-series from a single tertiary care center in Saudi Arabia.
Abstract Number: 2345

Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
Abstract Number: 2696

Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
Abstract Number: 1510

Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
Abstract Number: 0212

Biomarker-Guided Therapeutic Calculator for Personalized Management in Pregnant Patients with Autoimmune Rheumatic Diseases
Abstract Number: 1166

Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis
Abstract Number: 1602

Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis
Abstract Number: 1042

Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
Abstract Number: 2152

Blau Syndrome: features beyond the classic triad and proposal for clinical criteria
Abstract Number: 2476

Blinatumomab in rapid progressive systemic sclerosis
Abstract Number: 0732

Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)
Abstract Number: 0655

Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Abstract Number: 1687

Body Esteem and Sexual Function in Women with Systemic Lupus Erythematosus
Abstract Number: 1997

Bone health in patients with gout using real-world U.S. data
Abstract Number: 2431

Bone marrow- activity on 18F-FDG PET/CT as a Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus
Abstract Number: 2244

Bone Mineral Density Trajectories and Fracture Risk in Rheumatoid Arthritis: A 7-Year Longitudinal Analysis Using Group-Based Trajectory Modeling
Abstract Number: 1498

Both Race and Socioeconomic Status Affect Mortality in SLE
Abstract Number: 1112

Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
Abstract Number: 0996

Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
Abstract Number: 1264

Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt
Abstract Number: PP10

Breaking Through Scleroderma’s Invisible Struggles: From Isolation to Connection
Abstract Number: 1840

Breathomics in Systemic Lupus Erythematosus: uncovering non-invasive markers of disease activity
Abstract Number: 1770

Brepocitinib Inhibits Key Pathogenic Cytokine Signaling in Dermatomyositis Patients
Abstract Number: 0337

Bridging the Bone Gap: A Quality Improvement Project on Osteoporosis Screening Practices in a Teaching Institution
Abstract Number: 1982

Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Abstract Number: 1050

Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Abstract Number: 2169

Bridging the Gap: A National Needs Assessment of Rheumatology Fellowship Training in Adolescent and Young Adult Care
Abstract Number: 2156

Bridging the Gap: Juvenile Spondyloarthritis (JSpA) vs. Chronic Non-Bacterial Osteomyelitis (CNO)
Abstract Number: 0228

Bridging the Gap: Leveraging eConsultation to Improve Access to Quality Gout Care
Abstract Number: 1085

Bridging the Gap: The Use of Patient Joint Self-Assessment in RA Treatment Response Evaluation
Abstract Number: 2183

Bridging the Musculoskeletal Ultrasound Training Gap: Analysis of Confidence, Competency, and Clinical Readiness
Abstract Number: 1243

Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study
Abstract Number: 2530

Broad Screening of Inflammation-Associated Proteins Identifies Serum CCL19 and CCL2 as Versatile Biomarkers of Disease Activity in IgG4-Related Disease
Abstract Number: 2528

Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease
Abstract Number: 0020

Bulk RNA-sequencing of Leukocytoclastic Vasculitis Skin Biopsies Show Upregulation of Leukocyte Migration Genes
Abstract Number: 2437

Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
Abstract Number: 1394

Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].